



COPY OF PAPER  
ORIGINALLY FILED

PATENT  
Attorney Docket No. 218122  
DHHS Ref. E-323-00/0

#902  
Dai  
9/25/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hwu et al.

RECEIVED

SEP 13 2002

TECH CENTER 1600/2900

Art Unit: 6841

Application No. 09/803,578

Examiner: Michael C. Wilson

Filed: March 9, 2001

For: ACTIVATED DUAL SPECIFICITY  
LYMPHOCYTES AND THEIR  
METHODS OF USE

RESPONSE TO RESTRICTION REQUIREMENT,  
ELECTION OF SPECIES, AND NOTICE TO COMPLY  
WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE  
AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated July 8, 2002, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE SPECIFICATION:

Please replace paragraph [0047] with the following:

RI [0047] In one preferred embodiment, the tumor associated antigens recognized by the receptors of this invention are melanoma antigens. By way of example, melanoma specific T-cell receptors may recognize melanoma antigens in the context of HLA-A2.1 or HLA-A1. Examples of melanoma antigens which are recognized by the chimeric